GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Akso Health Group (NAS:AHG) » Definitions » Debt-to-EBITDA

Akso Health Group (Akso Health Group) Debt-to-EBITDA : -0.08 (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Akso Health Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Akso Health Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.35 Mil. Akso Health Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Akso Health Group's annualized EBITDA for the quarter that ended in Sep. 2023 was $-4.63 Mil. Akso Health Group's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Akso Health Group's Debt-to-EBITDA or its related term are showing as below:

AHG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.68   Med: -2.95   Max: -0.02
Current: -0.02

During the past 9 years, the highest Debt-to-EBITDA Ratio of Akso Health Group was -0.02. The lowest was -4.68. And the median was -2.95.

AHG's Debt-to-EBITDA is ranked worse than
100% of 75 companies
in the Medical Distribution industry
Industry Median: 2 vs AHG: -0.02

Akso Health Group Debt-to-EBITDA Historical Data

The historical data trend for Akso Health Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akso Health Group Debt-to-EBITDA Chart

Akso Health Group Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -2.95 -0.47 -4.68 - -

Akso Health Group Semi-Annual Data
Mar15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.60 - - - -0.08

Competitive Comparison of Akso Health Group's Debt-to-EBITDA

For the Medical Distribution subindustry, Akso Health Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akso Health Group's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Akso Health Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Akso Health Group's Debt-to-EBITDA falls into.



Akso Health Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Akso Health Group's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -13.066
=0.00

Akso Health Group's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.35 + 0) / -4.632
=-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.


Akso Health Group  (NAS:AHG) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Akso Health Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Akso Health Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Akso Health Group (Akso Health Group) Business Description

Traded in Other Exchanges
Address
No. 44, Moscow Road, Qianwan Bonded Port Area, Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building, Qingdao Pilot Free Trade Zone, Shandong, CHN
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It operates in two segments namely online marketplace and health devices. It generates the majority of revenue from the health devices segment.